381
Views
11
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

A randomized controlled trial testing an adherence-optimized Vitamin D regimen to mitigate bone change in adolescents being treated for acute lymphoblastic leukemia

ORCID Icon, ORCID Icon, , , , , & show all
Pages 2370-2378 | Received 22 Nov 2016, Accepted 25 Jan 2017, Published online: 20 Feb 2017

References

  • Haddy TB, Mosher RB, Reaman GH. Late effects in long-term survivors after treatment for childhood acute leukemia. Clin Pediatr (Phila). 2009;48:601–608.
  • Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children’s Oncology Group Study AALL0232. J Clin Oncol. 2016;34:2380–2388.
  • Mattano LA, Jr., Devidas M, Nachman JB, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13:906–915.
  • Makitie O, Heikkinen R, Toiviainen-Salo S, et al. Long-term skeletal consequences of childhood acute lymphoblastic leukemia in adult males: a cohort study. Eur J Endocrinol. 2013;168:281–288.
  • Cummings EA, Ma J, Fernandez CV, et al. Incident vertebral fractures in children with leukemia during the four years following diagnosis. J Clin Endocrinol Metab. 2015;100:3408–3417.
  • van der Sluis IM, van den Heuvel-Eibrink MM, Hählen K, et al. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr. 2002;141:204–210.
  • Halton J, Gaboury I, Grant R, et al. Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program. J Bone Miner Res. 2009;24:1326–1334.
  • Alos N, Grant RM, Ramsay T, et al. High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy. J Clin Oncol. 2012;30:2760–2767.
  • Orgel E, Mueske NM, Wren TA, et al. Early injury to cortical and cancellous bone from induction chemotherapy for adolescents and young adults treated for acute lymphoblastic leukemia. Bone. 2016;85:131–137.
  • Davies JH, Evans BA, Jenney ME, et al. In vitro effects of chemotherapeutic agents on human osteoblast-like cells. Calcif Tissue Int. 2002;70:408–415.
  • Winter C, Muller C, Brandes M, et al. Level of activity in children undergoing cancer treatment. Pediatr Blood Cancer. 2009;53:438–443.
  • Hartman A, te Winkel ML, van Beek RD, et al. A randomized trial investigating an exercise program to prevent reduction of bone mineral density and impairment of motor performance during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2009;53:64–71.
  • Rayar MS, Nayiager T, Webber CE, et al. Predictors of bony morbidity in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012;59:77–82.
  • Strauss AJ, Su JT, Dalton VM, et al. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001;19:3066–3072.
  • Vitanza NA, Hogan LE, Zhang G, et al. The progression of bone mineral density abnormalities after chemotherapy for childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2015;37:356–361.
  • Kaste SC, Rai SN, Fleming K, et al. Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006;46:77–87.
  • Looker AC, Johnson CL, Lacher DA, et al. Vitamin D status: United States, 2001–2006. NCHS Data Brief, US Department of Health and Human Services; 2011 [Internet]. [cited 2015 Mar 12]. Available from: http://wwwcdcgov/nchs/data/databriefs/db59pdf
  • World Health Organization. Health for the world’s adolescents [Internet]. [cited 2016 May 16]. Available from: http://www.who.int/maternal_child_adolescent/documents/adolescent/en/
  • Orgel E, Mueske NM, Sposto R, et al. Limitations of body mass index to assess body composition due to sarcopenic obesity during leukemia therapy. Leuk Lymphoma 2016. [Epub ahead of print]. doi: 10.3109/10428194.2015.1136741
  • Antony R, Sheng X, Ehsanipour EA, et al. Vitamin D protects acute lymphoblastic leukemia cells from dexamethasone. Leuk Res. 2012;36:591–593.
  • Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930.
  • Baio G, Barbagallo M, D’Avola G, et al. Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis. Exp Opin Pharmacother. 2011;12:257–268.
  • Ilahi M, Armas LA, Heaney RP. Pharmacokinetics of a single, large dose of cholecalciferol. Am J Clin Nutr. 2008;87:688–691.
  • Arpadi SM, McMahon D, Abrams EJ, et al. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics. 2009;123:e121–e126.
  • Rangul V, Holmen TL, Kurtze N, et al. Reliability and validity of two frequently used self-administered physical activity questionnaires in adolescents. BMC Med Res Methodol. 2008;8:47.
  • Ross AC, Taylor CL, Yaktine AL, del Valle HB. Institute of Medicine: dietary reference intakes for calcium and vitamin D. Washington (DC): The National Academies Press; 2011.
  • Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999–2010. JAMA. 2012;307:483–490.
  • Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–281.
  • Withycombe JS, Post-White JE, Meza JL, et al. Weight patterns in children with higher risk ALL: a report from the Children’s Oncology Group (COG) for CCG 1961. Pediatr Blood Cancer. 2009;53:1249–1254.
  • Tepper S, Shahar DR, Geva D, et al. Predictors of serum 25(Oh)D increase following bimonthly supplementation with 100,000 IU vitamin D in healthy, men aged 25–65 years. J Steroid Biochem Mol Biol. 2014;144:163–166.
  • Camozzi V, Frigo AC, Zaninotto M, et al. 25-Hydroxycholecalciferol response to single oral cholecalciferol loading in the normal weight, overweight, and obese. Osteoporos Int. 2016;27:2593–2602.
  • Cipriani C, Romagnoli E, Scillitani A, et al. Effect of a single oral dose of 600,000 IU of cholecalciferol on serum calciotropic hormones in young subjects with vitamin D deficiency: a prospective intervention study. J Clin Endocrinol Metab. 2010;95:4771–4777.
  • Bailey DA, McKay HA, Mirwald RL, et al. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study. J Bone Miner Res. 1999;14:1672–1679.
  • McCormick DP, Ponder SW, Fawcett HD, et al. Spinal bone mineral density in 335 normal and obese children and adolescents: evidence for ethnic and sex differences. J Bone Miner Res. 1991;6:507–513.
  • Zhao LJ, Jiang H, Papasian CJ, et al. Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res. 2008;23:17–29.
  • Leonard MB, Shults J, Wilson BA, et al. Obesity during childhood and adolescence augments bone mass and bone dimensions. Am J Clin Nutr. 2004;80:514–523.
  • Gilsanz V, Chalfant J, Mo AO, et al. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab. 2009;94:3387–3393.
  • Lee MJ, Pramyothin P, Karastergiou K, et al. Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity. Biochim Biophys Acta. 2014;1842:473–481.
  • Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10:CD001347.
  • Lethaby C, Wiernikowski J, Sala A, et al. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. J Pediatr Hematol Oncol. 2007;29:613–616.
  • Wiernikowski JT, Barr RD, Webber C, et al. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin’s lymphoma: results of a pilot study. J Oncol Pharm Prac. 2005;11:51–56.
  • Barr RD, Guo CY, Wiernikowski J, et al. Osteopenia in children with acute lymphoblastic leukemia: a pilot study of amelioration with Pamidronate. Med Pediatr Oncol. 2002;39:44–46.
  • Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 2008;1143:123–150.
  • Bhatia S, Landier W, Hageman L, et al. 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2014;124:2345–2353.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.